Основная статистика
| CIK | 1279695 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to UNIVERSAL BIOSENSORS INC
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52607 Universal Biosensors |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) June 30, 2025 Universal Biosensors, Inc. |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Commission File Number: 000-52607 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 98-0424072 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Universal Biosensors, Inc. 1 Corporate Avenue, Rowv |
|
| May 12, 2025 |
Presentation by Mr. Peter Mullin, Chief Executive Officer & Managing Director Exhibit 99.1 |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 12, 2025 Universal Biosensors, Inc. |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52607 Universal Biosensor |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a – 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confi |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a – 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confi |
|
| April 1, 2025 |
Exhibit 99.1 Managing Director and Chief Executive Officer Appointment Universal Biosensors Inc. (ASX: UBI) announces the following executive changes: John Sharman Resignation as Managing Director and CEO John Sharman has decided to step down from the Managing Director and CEO role for personal reasons effective April 1, 2025. John has led the business for 5 years and in that time has transformed |
|
| April 1, 2025 |
Offer Letter, dated March 31, 2025, between Universal Biosensors, Inc. and Peter Mullin. Exhibit 10.2 Universal Biosensors, Inc. ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 31 March 2025 Peter Mullin Managing Director and Chief Executive Officer Apartment 503, 84 Cutter Street Richmond 3121 Dear Peter MD and CEO Incentive Program The Remuneration |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) April 1, 2025 Universal Biosensors, Inc. |
|
| April 1, 2025 |
Exhibit 10.1 31 March 2025 Peter Mullin Apartment 503, 84 Cutter Street, Richmond, Vic 3121 Private and confidential Dear Peter Letter of offer We are pleased to offer you updated terms of employment with Universal Biosensors Pty Ltd (ABN 35 098 234 309) (Company) on the terms and conditions of employment set out in this letter. 1. Your employment 1.1 Commencement Your employment with the Company |
|
| February 26, 2025 |
Exhibit 32.0 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 * In connection with the annual report of Universal Biosensors, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Co |
|
| February 26, 2025 |
Exhibit 4.3 Description of Securities Description of Registrant’s Securities Registered Pursuant to Section 12 of The Securities Exchange Act of 1934 The following is a brief description of the securities of Universal Biosensors, Inc. ( the “company,” “we,” “us,” or “our”) registered pursuant to Section 12 of the Securities Exchange Act, as amended (the “Exchange Act”). The following description o |
|
| February 26, 2025 |
Exhibit 21.0 List of subsidiaries Subsidiary of Universal Biosensors Inc. Jurisdiction of Incorporation Universal Biosensors Pty Ltd. Australia Hemostasis Reference Laboratory Inc. Canada Universal Biosensors B.V. The Netherlands Universal Biosensors LLC Delaware, U.S. |
|
| February 26, 2025 |
Exhibit 13.0 Universal Biosensors, Inc. 2024 Annual Report Contents Management’s Discussion and Analysis of Financial Condition and Results of Operations F-2 Report of Independent Registered Public Accounting Firm F-9 Consolidated Balance Sheets F-10 Consolidated Statements of Comprehensive Income/(Loss) F-11 Consolidated Statements of Changes in Stockholders’ Equity and Comprehensive Income/(Loss |
|
| February 26, 2025 |
Exhibit 19.0 Securities Trading Policy 1. Introduction Universal Biosensors, Inc. (UBI or Company) is a Delaware incorporated company whose shares of common stock (Shares) traded in the forms of CHESS Depositary Interests (CDIs) are quoted on Australian Securities Exchange (ASX). For the purposes of this policy, “UBI Securities” include: • Shares, CDIs and any other securities (including preferred |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-52607 Universal Biosensors, Inc |
|
| January 15, 2025 |
Equity award agreement between Mr. Peter Mullin and Universal Biosensors, Inc. Exhibit 10.2 Universal Biosensors, Inc. ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 9 January 2025 Peter Mullin Finance Director and Chief Financial Officer Apartment 503, 84 Cutter Street Richmond 3121 Dear Peter Finance Director Incentive Program The Remuner |
|
| January 15, 2025 |
Equity award agreement between Mr. John Sharman and Universal Biosensors, Inc. Exhibit 10.1 Universal Biosensors, Inc. ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 9 January 2025 John Sharman Chief Executive Officer 5 Ruby Street, Hawthorn Vic 3122 Dear John Managing Director Incentive Program The Remuneration & Nomination Committee, on b |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) January 15, 2025 Universal Biosensors, Inc. |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 31, 2024 Universal Biosensors, Inc. |
|
| January 7, 2025 |
Exhibit 10.1 29/12/24 Peter Mullin Apartment 503, 84 Cutter St Richmond 3121 Private and confidential Dear Peter Letter of offer We are pleased to offer you employment with Universal Biosensors Pty Ltd (ABN 35 098 234 309) (Company) on the terms and conditions of employment set out in this letter. 1. Your employment 1.1 Commencement Your employment with the Company on the terms and conditions in t |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52607 Universal Biose |
|
| August 2, 2024 |
Exhibit 10.16 Underwriting Agreement Viburnum Funds Pty Ltd and Universal Biosensors, Inc. Table of contents Table of contents 1. Definitions and interpretation clauses 1 1.1 Definitions 1 1.2 Interpretation 9 1.3 Official quotation 10 2. Underwriter's rights and obligations 10 2.1 Appointment 10 2.2 Sub-Underwriters 10 2.3 Conditions precedent 10 2.4 Benefit of conditions precedent 11 2.5 Conditi |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52607 Universal Biosensors |
|
| August 2, 2024 |
Exhibit 10.17 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF UNIVERSAL BIOSENSORS, INC. Universal Biosensors, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Corpo |
|
| May 30, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 30, 2024 Universal Biosensors, Inc. |
|
| May 30, 2024 |
Presentation by Mr. John Sharman, Chief Executive Officer Exhibit 99.1 |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Commission File Number: 000-52607 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 98-0424072 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Universal Biosensors, Inc. 1 Corporate Avenue, Rowv |
|
| May 3, 2024 |
AU:UBIO / Universal Biosensors, Inc. / Viburnum Funds Pty Ltd - SC 13D/A Activist Investment SC 13D/A 1 tm2413540d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2) Under the Securities Exchange Act of 1934* Universal Biosensors, Inc. (Name of Issuer) Common Stock, par value US$0.0001 (Title of Class of Securities) Not Applicable (CUSIP Number) Viburnum Funds Pty Ltd Attention: David St Quintin 31 Carrington Street N |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52607 Universal Biosensor |
|
| May 2, 2024 |
Term sheet between Viburnum Funds Pty Ltd and Universal Biosensors, Inc. Exhibit 10.15 CONFIDENTIAL UNIVERSAL BIOSENSORS, INC. EQUITY UNDERWRITING TERM SHEET (Term Sheet) 1. Investor Viburnum Funds Pty Ltd (or its nominees or a special purpose investment trust) (Investor). 2. Company Universal Biosensors, Inc. (the Company). 3. Underwriting Investor offers to fully underwrite a A$10,000,000.00 (Underwritten Amount) non- renounceable entitlement offer of the Company’s o |
|
| April 11, 2024 |
-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) April 10, 2024 Universal Biosensors, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-52607 98-0424072 (State or Other Jurisdiction of Incorporation) (Co |
|
| April 11, 2024 |
Exhibit 99.1 Universal Biosensors, Inc. ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 11 April 2024 Dear Securityholder, UNIVERSAL BIOSENSORS, INC. ARBN 121 559 993 - ENTITLEMENT OFFER - NOTIFICATION TO INELIGIBLE SECURITYHOLDERS OF ENTITLEMENT OFFER Today Unive |
|
| April 11, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF UNIVERSAL BIOSENSORS, INC. Universal Biosensors, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Corpora |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a – 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confi |
|
| March 29, 2024 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) March 25, 2024 Universal Biosensors, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-52607 98-0424072 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) March 15, 2024 Universal Biosensors, Inc. (Exact Name of Registrant as Specified in Its Charter) -12-31 -12-31 Delaware 000-52607 98-0424072 (State or Other Jurisdiction of Incorporati |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 15, 2024 |
Amended and Restated Bylaws of Universal Biosensors, Inc. Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF UNIVERSAL BIOSENSORS, INC. (hereinafter called the “Corporation”) ARTICLE I DEFINITIONS AND CONSTRUCTION Section 1.1 Definitions. In these Amended and Restated By-laws: “ASTC” means ASX Settlement and Transfer Corporation Pty Ltd and any successor entity. “ASTC Settlement Rules” means the settlement rules of the ASTC as amended from time to time. “ASX” m |
|
| March 5, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) February 28, 2024 Universal Biosensors, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-52607 98-0424072 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) February 28, 2024 Universal Biosensors, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-52607 98-0424072 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 29, 2024 |
Exhibit 32.0 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 * In connection with the annual report of Universal Biosensors, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Co |
|
| February 29, 2024 |
Exhibit 13.0 Universal Biosensors, Inc. 2023 Annual Report Contents Management’s Discussion and Analysis of Financial Condition and Results of Operations F-2 Report of Independent Registered Public Accounting Firm F-9 Consolidated Balance Sheets F-10 Consolidated Statements of Comprehensive Income/(Loss) F-11 Consolidated Statements of Changes in Stockholders’ Equity and Comprehensive Income/(Loss |
|
| February 29, 2024 |
Exhibit 21.0 List of subsidiaries Subsidiary of Universal Biosensors Inc. Jurisdiction of Incorporation Universal Biosensors Pty Ltd. Australia Hemostasis Reference Laboratory Inc. Canada Universal Biosensors B.V. The Netherlands Universal Biosensors LLC Delaware, U.S. |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-52607 Universal Biosensors, Inc |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52607 Universal Biose |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52607 Universal Biosensors |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Commission File Number: 000-52607 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 98-0424072 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Universal Biosensors, Inc. 1 Corporate Avenue, Rowv |
|
| May 22, 2023 |
Presentation by Mr. John Sharman, Chief Executive Officer Exhibit 99.1 |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 22, 2023 Universal Biosensors, Inc. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52607 Universal Biosensor |
|
| April 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a – 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confi |
|
| February 24, 2023 |
Exhibit 13.0 Universal Biosensors, Inc. 2022 Annual Report Contents Management’s Discussion and Analysis of Financial Condition and Results of Operations F-2 Report of Independent Registered Public Accounting Firm F-11 Consolidated Balance Sheets F-12 Consolidated Statements of Comprehensive Income/(Loss) F-13 Consolidated Statements of Changes in Stockholders’ Equity and Comprehensive Income/(Los |
|
| February 24, 2023 |
Exhibit 32.0 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 * In connection with the annual report of Universal Biosensors, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Co |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 -12-31 FY 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-52607 Universal |
|
| February 24, 2023 |
Exhibit 21 List of subsidiaries Subsidiary of Universal Biosensors Inc. Jurisdiction of Incorporation Universal Biosensors Pty Ltd. Australia Hemostasis Reference Laboratory Inc. Canada Universal Biosensors B.V. The Netherlands Universal Biosensors LLC Delaware, U.S. |
|
| January 17, 2023 |
AU:UBI / Universal Biosensors Inc / Richmond Hill Capital Pty Ltd - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* Universal Biosensors, Inc. (Name of Issuer) Common Stock, par value US$0.0001 (Title of Class of Securities) Not Applicable (CUSIP Number) Jan |
|
| January 17, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT January 17, 2023 Pursuant to Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees that RICHMOND HILL CAPITAL PTY LTD ("Richmond Hill Capital") may file as necessary on behalf of the undersigned with the Securities and Exchange Commission a Schedule 13G or Schedule 13D and any amendments th |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52607 Universal Biose |
|
| August 10, 2022 |
Underwriting Agreement between Viburnum Funds Pty Ltd and Universal Biosensors, Inc. Exhibit 10.18 Underwriting Agreement Viburnum Funds Pty Ltd and Universal Biosensors, Inc. Ref 1116539 Error! Unknown document property name. Level 20, 240 St Georges Terrace, Perth WA 6000 Australia PO Box 7222, Cloisters Square WA 6850 Australia Telephone +61 8 6559 6500 Facsimile 1300 704 211 (Australia) +61 28507 6580 (International) hwlebsworth.com.au Table of contents 1. Definitions and inte |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52607 Universal Biosensors |
|
| June 21, 2022 |
Presentation by Mr. John Sharman, Chief Executive Officer Exhibit 99.1 |
|
| June 21, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) June 21, 2022 Universal Biosensors, Inc. |
|
| May 31, 2022 |
AU:UBI / Universal Biosensors Inc / Viburnum Funds Pty Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934* Universal Biosensors, Inc. (Name of Issuer) Common Stock, par value US$0.0001 (Title of Class of Securities) Not Applicable (CUSIP Number) Viburnum Funds Pty Ltd Attention: David St Quintin 31 Carrington Street Nedlands, Western Australia, Australia, 600 |
|
| May 25, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 23, 2022 Universal Biosensors, Inc. |
|
| May 17, 2022 |
SD 1 ubi20220516sd.htm FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Commission File Number: 000-52607 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 98-0424072 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Universal Biosensors |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a – 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confi |
|
| April 29, 2022 |
DEF 14A 1 ubi20220425def14a.htm FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a – 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropria |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52607 Universal Biosensor |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) April 19, 2022 Universal Biosensors, Inc. |
|
| April 22, 2022 |
Exhibit 99.1 Universal Biosensors, Inc. ABN 67 950 836 446 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone: +61 3 9213 9000 Facsimile: +61 3 9213 9099 Email: [email protected] www.universalbiosensors.com 20 April 2022 Dear Securityholder, UNIVERSAL BIOSENSORS INC ARBN 121 559 993 - ENTITLEMENT OFFER - NOTIFICATION TO INELIGIBLE SECURITYHOLDERS OF ENTITLEMENT OFFER On 20 Ap |
|
| April 22, 2022 |
Rule 135c Written Notice to the Company’s Stockholders. Exhibit 99.1 Universal Biosensors, Inc. ABN 67 950 836 446 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone: +61 3 9213 9000 Facsimile: +61 3 9213 9099 Email: [email protected] www.universalbiosensors.com 20 April 2022 Dear Securityholder, UNIVERSAL BIOSENSORS INC ARBN 121 559 993 - ENTITLEMENT OFFER - NOTIFICATION TO INELIGIBLE SECURITYHOLDERS OF ENTITLEMENT OFFER On 20 Ap |
|
| April 22, 2022 |
DEFA14A 1 ubi20220421defa14a.htm FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) April 19, 2022 Universal Biosensors, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-52607 98-0424072 (State or Oth |
|
| April 22, 2022 |
PRE 14A 1 ubi20220420pre14a.htm FORM PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a – 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropria |
|
| March 7, 2022 |
Exhibit 10.1 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (?Agreement?) is made and entered into as of the day of , 20, by and between Universal Biosensors, Inc., a Delaware corporation (the ?Company?) and (?Indemnitee?). WHEREAS, Indemnitee is director and/or officer of the Company; WHEREAS, both the Company and Indemnitee recognize the increased risk of litigation and other claims be |
|
| March 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) March 7, 2022 Universal Biosensors, Inc. |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ Annual Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 -12-31 FY 2021 or ☐ Transition Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-52607 Universal |
|
| February 24, 2022 |
Exhibit 13.0 Universal Biosensors, Inc. 2021 Annual Report Contents Management’s Discussion and Analysis of Financial Condition and Results of Operations F-2 Report of Independent Registered Public Accounting Firm F-10 Consolidated Balance Sheets F-11 Consolidated Statements of Comprehensive Income/(Loss) F-12 Consolidated Statements of Changes in Stockholders’ Equity and Comprehensive Income/(Los |
|
| February 24, 2022 |
Exhibit 21 List of subsidiaries Subsidiary of Universal Biosensors Inc. Jurisdiction of Incorporation Universal Biosensors Pty Ltd. Australia Hemostasis Reference Laboratory Inc. Canada Universal Biosensors B.V. The Netherlands Universal Biosensors LLC Delaware, U.S. |
|
| February 24, 2022 |
Exhibit 32.0 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 * In connection with the annual report of Universal Biosensors, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Co |
|
| January 11, 2022 |
AU:UBI / Universal Biosensors Inc / Richmond Hill Capital Pty Ltd - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* Universal Biosensors, Inc. (Name of Issuer) Common Stock, par value US$0.0001 (Title of Class of Securities) Not Applicable (CUSIP Number) Jan |
|
| January 11, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT January 11, 2022 Pursuant to Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees that RICHMOND HILL CAPITAL PTY LTD ("Richmond Hill Capital") may file as necessary on behalf of the undersigned with the Securities and Exchange Commission a Schedule 13G or Schedule 13D and any amendments th |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52607 Universal Biose |
|
| September 17, 2021 |
Exhibit 10.2 Universal Biosensors Inc. Employee Incentive Plan Plan Rules 1. Introduction This Plan sets outs the rules under which Eligible Persons may, at the invitation of the Company, acquire Awards to acquire CDIs in the Company. 2. Definitions and Interpretation 2.1 In these rules, unless the contrary intention appears, the following terms have the following meanings: ASX means ASX Limited A |
|
| September 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) August 19, 2021 Universal Biosensors, Inc. |
|
| September 17, 2021 |
EX-10.1 2 ex284061.htm EXHIBIT 10.1 Exhibit 10.1 Rules of Universal Biosensors Inc. Option Plan 1 Definitions and interpretation 1.1 Definitions In these Rules, unless the contrary intention appears: (1) Accelerated Vesting Event means the occurrence of: (a) a Special Circumstance in respect of a Participant; or (b) a Control Event; (2) Applicable Law means one or more, as the context requires of: |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52607 Universal Biosensors |
|
| July 6, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 ubi202107038k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) June 30, 2021 Universal Biosensors, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-52607 98-0424072 (State or Other Jurisdictio |
|
| July 6, 2021 |
Presentation by Mr. John Sharman, Chief Executive Officer EX-99.1 2 ex261822.htm EXHIBIT 99.1 Exhibit 99.1 |
|
| May 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Commission File Number: 000-52607 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 98-0424072 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Universal Biosensors, Inc. 1 Corporate Avenue, Rowv |
|
| April 30, 2021 |
10-Q 1 ubi2021033110q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File |
|
| April 30, 2021 |
DEF 14A 1 ubi20210419def14a.htm FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a – 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by Registrant ☒ Filed by party other than Registrant ☐ Check the appropriate box: ☐ |
|
| March 18, 2021 |
EX-10.4 5 ex235029.htm EXHIBIT 10.4 Exhibit 10.4 Universal Biosensors Inc. Employee Share Plan Plan Rules 1. Introduction This Plan sets outs the rules under which Eligible Persons may, at the invitation of the Company, acquire Shares in the Company. 2. Definitions and Interpretation 2.1 In these rules, unless the contrary intention appears, the following terms have the following meanings: ASX mea |
|
| March 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) January 27, 2021 Universal Biosensors, Inc. |
|
| March 18, 2021 |
Award Agreement between Universal Biosensors, Inc. and Mr. John Sharman, dated February 28, 2021 Exhibit 10.3 Universal Biosensors Pty Ltd ABN 35 098 234 309 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 28 February 2021 John Sharman Chief Executive Officer 5 Ruby Street Hawthorn VIC 3122 Dear John, 2021 Bonus Program The 2021 Bonus Program for the Senior Management Team is |
|
| March 18, 2021 |
Deed of Surrender and Lease between Universal Biosensors Pty Ltd and Bowmayne Pty Ltd EX-10.1 2 ex235026.htm EXHIBIT 10.1 Exhibit 10.1 BOWMAYNE PTY. LTD. A.C.N. 126 501 755 (“Lessor”) AND: UNIVERSAL BIOSENSORS PTY. LTD. A.B.N. 35 098 234 309 (“Lessee”) DEED OF SURRENDER PREMISIS: 1 CORPORATE AVENUE, ROWVILLE 3178 Michael Snider Legal Practitioner P.O. Box 325 ELSTERNWICK 3185 Telephone: 9571 1433 Facsimile: 9571 2033 Email: [email protected] 1 THIS DEED OF SURRENDER is mad |
|
| March 18, 2021 |
Award Agreement between Universal Biosensors, Inc. and Mr. Salesh Balak, dated February 28, 2021 Exhibit 10.2 Universal Biosensors Pty Ltd ABN 35 098 234 309 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 28 February 2021 Salesh Balak Chief Financial Officer 46 Canterbury Avenue Sunbury VIC 3429 Dear Salesh, 2021 Bonus Program The 2021 Bonus Program for the Senior Management |
|
| March 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) March 17, 2021 Universal Biosensors, Inc. |
|
| February 24, 2021 |
Exhibit 32.0 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 * In connection with the annual report of Universal Biosensors, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Co |
|
| February 24, 2021 |
EX-21 3 ex226050.htm EXHIBIT 21 Exhibit 21 LIST OF SUBSIDIARIES Universal Biosensors Pty Ltd. Hemostasis Reference Laboratory Inc. |
|
| February 24, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 OR ? Transition Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 000-52607 Universal Biosensors, Inc. (Exact name of |
|
| February 24, 2021 |
Exhibit 13.0 Universal Biosensors, Inc. 2020 Annual Report Contents Management’s Discussion and Analysis of Financial Condition and Results of Operations F-2 Report of Independent Registered Public Accounting Firm F-12 Consolidated Balance Sheets F-13 Consolidated Statements of Comprehensive Income/(Loss) F-14 Consolidated Statements of Changes in Stockholders’ Equity and Comprehensive Income/(Los |
|
| January 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* Universal Biosensors, Inc. (Name of Issuer) Common Stock, par value US$0.0001 (Title of Class of Securities) Not Applicable (CUSIP Number) Jan |
|
| January 14, 2021 |
EX-99.1 2 tm212741d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT January 11, 2021 Pursuant to Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees that RICHMOND HILL CAPITAL PTY LTD ("Richmond Hill Capital") may file as necessary on behalf of the undersigned with the Securities and Exchange Commission a Schedu |
|
| January 11, 2021 |
SC 13D 1 tm212740d1sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934* Universal Biosensors, Inc. (Name of Issuer) Common Stock, par value US$0.0001 (Title of Class of Securities) Not Applicable (CUSIP Number) Viburnum Funds Pty Ltd Attention: David St Quintin 31 Carrington Street Nedlands, Western Austral |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORTPURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-52607 Universal Bios |
|
| September 8, 2020 |
Exhibit 99.1 JOINT FILING AGREEMENT July 20, 2016 Pursuant to Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees that VIBURNUM FUNDS PTY LTD ("Viburnum") may file as necessary on behalf of the undersigned with the Securities and Exchange Commission a Schedule 13G or Schedule 13D and any amendments thereto in respect of sha |
|
| September 8, 2020 |
UBI / UNIVERSAL BIOSENSORS INC / Viburnum Funds Pty Ltd - SC 13D Activist Investment SC 13D 1 tm2030369d1sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934* Universal Biosensors, Inc. (Name of Issuer) Common Stock, par value US$0.0001 (Title of Class of Securities) Not Applicable (CUSIP Number) Viburnum Funds Pty Ltd Attention: David St Quintin 31 Carrington Street Nedlands, Western Austra |
|
| July 24, 2020 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 24, 2020 |
EX-99.1 Exhibit 99.1 Annual General Meeting 24 July 2020Exhibit 99.1 Annual General Meeting 24 July 2020 Important Disclaimer • This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. This presentation is not financial advice and has been prepared without taking into account the objectives, financial situation or needs |
|
| July 24, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) July 24, 2020 Universal Biosensors, Inc. |
|
| July 14, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a – 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by Registrant ☒ Filed by party other than Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| July 10, 2020 |
UBI / UNIVERSAL BIOSENSORS INC / Cvc Ltd - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 3)* Universal Biosensors, Inc. (Name of Issuer) Common Stock, par value US$0.0001 (Title of Class of Securities) Not Applicable (CUSIP Number) Ju |
|
| July 10, 2020 |
Exhibit 1 JOINT FILING AGREEMENT July 10, 2020 Pursuant to Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees that CVC Limited ("CVC") may file as necessary on behalf of the undersigned with the Securities and Exchange Commission a Schedule 13G or Schedule 13D and any amendments thereto in respect of shares of Universal Biosensors, Inc. |
|
| June 4, 2020 |
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Commission File Number: 000-52607 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 98-0424072 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Universal Biosensors, Inc. 1 Corporate Avenue, R |
|
| May 29, 2020 |
DEF 14A 1 d875410ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a – 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by Registrant ☒ Filed by party other than Registrant ☐ Check the appropria |
|
| May 26, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 25, 2020 Universal Biosensors, Inc. |
|
| May 26, 2020 |
EX-99.1 Exhibit 99.1 Universal Biosensors, Inc. ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 25 May 2020 Commencement Date of New Chief Executive Officer On 6 March 2020, Universal Biosensors, Inc. (ASX Code: UBI, “UBI”) announced the appointment of John Sharma |
|
| May 1, 2020 |
EX-10.1 Exhibit 10.1 Dated 3 March 2020 Chief Executive Officer - Executive Service Parties Universal Biosensors Pty Ltd (ACN 098 234 309) John Sharman Contents 1. Definitions and interpretation 1 2. Warranties 5 3. Commencement 5 4. Inherent Requirement 5 5. Position and Duties 5 6. Employer’s directions 6 7. Place of work 6 8. Hours of work 7 9. Remuneration 7 10. Equity Incentive Plan 7 11. Met |
|
| May 1, 2020 |
10-Q/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2020 |
10-K/A 1 d920102d10ka.htm 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ☒ Annual Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 OR ☐ Transition Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 000-52607 Univer |
|
| April 24, 2020 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 26, 2020 |
EX-4.3 Exhibit 4.3 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a brief description of the securities of Universal Biosensors, Inc. (“UBI”, “our company”, the “company”, “we”, “us”, or “our”) registered pursuant to Section 12 of the Securities Exchange Act, as amended (the “Exchange Act”). We refer in this descript |
|
| February 26, 2020 |
EX-32.0 Exhibit 32.0 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 * In connection with the annual report of Universal Biosensors, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers o |
|
| February 26, 2020 |
UBI / UNIVERSAL BIOSENSORS INC 10-K - Annual Report - 10-K 10-K 1 d875138d10k.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 OR ☐ Transition Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 000-52607 Universal Bio |
|
| February 26, 2020 |
EX-21 Exhibit 21 LIST OF SUBSIDIARIES Universal Biosensors Pty Ltd. Hemostasis Reference Laboratory Inc. |
|
| February 13, 2020 |
UBI / UNIVERSAL BIOSENSORS INC / Cvc Ltd - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tm207994d1sc13ga.htm SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 2)* Universal Biosensors, Inc. (Name of Issuer) Common Stock, par value US$0.0001 (Title of Class |
|
| February 13, 2020 |
Exhibit 1 JOINT FILING AGREEMENT February 13, 2020 Pursuant to Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees that CVC Limited ("CVC") may file as necessary on behalf of the undersigned with the Securities and Exchange Commission a Schedule 13G or Schedule 13D and any amendments thereto in respect of shares of Universal Biosensors, Inc. |
|
| December 2, 2019 |
UBI / UNIVERSAL BIOSENSORS INC / Viburnum Funds Pty Ltd - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934* Universal Biosensors, Inc. (Name of Issuer) Common Stock, par value US$0.0001 (Title of Class of Securities) Not Applicable (CUSIP Number) Viburnum Funds Pty Ltd Attention: David St Quintin 31 Carrington Street Nedlands, Western Australia, Australia, 6009 (Name, Address a |
|
| November 4, 2019 |
UBI / UNIVERSAL BIOSENSORS INC 10-Q - Quarterly Report - 10-Q 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 4, 2019 |
EX-10.23 2 d813466dex1023.htm EX-10.23 Exhibit 10.23 *Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. The redacted confidential portions of the exhibit are marked by [***]. COMMERCIAL & DISTRIBUTION AGREEMENT between Siemens Healthcare Diagnostics Inc. and Universal Biosensors Pty |
|
| September 23, 2019 |
EX-99.1 Exhibit 99.1 Universal Biosensors, Inc. ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 23 September 2019 UBI and Siemens Execute Definitive Agreements Universal Biosensors, Inc. (UBI) is pleased to advise that it has executed the Definitive Agreements wit |
|
| September 23, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) September 18, 2019 Universal Biosensors, Inc. |
|
| September 9, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) September 9, 2019 Universal Biosensors, Inc. |
|
| September 9, 2019 |
Appendix 3C Announcement of buy-back (except minimum holding buy-back) EX-99.1 Exhibit 99.1 Universal Biosensors, Inc. ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 9 September 2019 UBI: Siemens negotiations, business update and on-market buy-back Universal Biosensors, Inc. (UBI) is pleased to provide an update on its commercial ne |
|
| August 22, 2019 |
EX-99.1 Exhibit 99.1 Universal Biosensors, Inc. ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 22 August 2019 Term Sheet Extension On 8 February 2019, Universal Biosensors, Inc. and Universal Biosensors Pty Ltd (collectively “UBI”) entered into a term sheet agree |
|
| August 22, 2019 |
8-K 1 d768131d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) August 21, 2019 Universal Biosensors, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-52607 98-0424072 (State or Other Jurisdiction of I |
|
| July 25, 2019 |
UBI / UNIVERSAL BIOSENSORS INC 10-Q - Quarterly Report - 10-Q 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 27, 2019 |
EX-99.1 Exhibit 99.1 Universal Biosensors, Inc. ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 26 June 2019 Business Update Universal Biosensors, Inc. (UBI) is pleased to provide an update on the following matters: • Cash update • CEO Transition Cash Update In ou |
|
| June 27, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) June 26, 2019 Universal Biosensors, Inc. |
|
| June 26, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) June 25, 2019 Universal Biosensors, Inc. |
|
| June 26, 2019 |
Chief Executive Officer’s Address Annual General Meeting EX-99.1 Exhibit 99.1 Universal Biosensors Inc ARBN 121 559 993 1 Corporate Avenue Rowville VIC 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 25 June 2019 Chief Executive Officer’s Address Annual General Meeting Good morning, ladies and gentlemen, I am happy to welcome you to our Rowville office for Universal Biosen |
|
| May 30, 2019 |
EX-99.1 Exhibit 99.1 Universal Biosensors, Inc. ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 30 May 2019 Term Sheet Extension On 8 February 2019, Universal Biosensors, Inc. and Universal Biosensors Pty Ltd (collectively “UBI”) entered into a term sheet agreemen |
|
| May 30, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 29, 2019 Universal Biosensors, Inc. |
|
| May 13, 2019 |
UBI / UNIVERSAL BIOSENSORS INC SD SD SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Commission File Number: 000-52607 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 98-0424072 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Universal Biosensors, Inc. 1 Corporate Avenue, R |
|
| April 30, 2019 |
UBI / UNIVERSAL BIOSENSORS INC DEF 14A DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 30, 2019 |
EX-10.22 Exhibit 10.22 CONFIDENTIAL SETTLEMENT MATERIAL SUBJECT TO FRE 408 SETTLEMENT TERM SHEET Confidentiality Standard confidentiality provision Inadmissibility of Settlement Negotiations All discussions, communications, and materials exchanged in the course of the party’s negotiation pursuant to and agreed upon through this term sheet shall be protected by Federal Rule of Evidence 408 and all |
|
| April 30, 2019 |
UBI / UNIVERSAL BIOSENSORS INC 10-Q Quarterly Report 10-Q 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 8, 2019 |
EX-99.3 2018 Financial Results Mr. Rick Legleiter – Chief Executive Officer Mr. Salesh Balak – Chief Financial Officer Exhibit 99.3 Important Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. This presentation is not financial advice and has been prepared without taking into account the objectives, fin |
|
| March 8, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) March 8, 2019 Universal Biosensors, Inc. |
|
| March 8, 2019 |
EX-99.1 2 d719310dex991.htm EX-99.1 Exhibit 99.1 Universal Biosensors Inc ARBN 121 559 993 1 Corporate Avenue Rowville VIC 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 8 March 2019 Universal Biosensors, Inc. (UBI) is pleased to provide an update on its business activities and a review of its fiscal year ended 31 D |
|
| March 8, 2019 |
Universal Biosensors Announces Resignation of CEO Rick Legleiter EX-99.2 Exhibit 99.2 Universal Biosensors Inc ARBN 121 559 993 1 Corporate Avenue Rowville VIC 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 8 March 2019 Universal Biosensors Announces Resignation of CEO Rick Legleiter Universal Biosensors, Inc. (ASX: UBI) advises that its Chief Executive Officer, Mr. Rick Legleite |
|
| March 6, 2019 |
EX-99.1 2 tv515587ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT July 20, 2016 Pursuant to Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees that VIBURNUM FUNDS PTY LTD ("Viburnum") may file as necessary on behalf of the undersigned with the Securities and Exchange Commission a Schedule 13G or Schedule 13D an |
|
| March 6, 2019 |
UBI / UNIVERSAL BIOSENSORS INC / Viburnum Funds Pty Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934* Universal Biosensors, Inc. (Name of Issuer) Common Stock, par value US$0.0001 (Title of Class of Securities) Not Applicable (CUSIP Number) Viburnum Funds Pty Ltd Attention: David St Quintin 31 Carrington Street Nedlands, Western Australia, Australia, 600 |
|
| February 22, 2019 |
EX-32.0 Exhibit 32.0 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 * In connection with the annual report of Universal Biosensors, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers o |
|
| February 22, 2019 |
EX-21 Exhibit 21 LIST OF SUBSIDIARIES Universal Biosensors Pty Ltd. Hemostasis Reference Laboratory Inc. |
|
| February 22, 2019 |
UBI / UNIVERSAL BIOSENSORS INC FORM 10-K (Annual Report) Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 14, 2019 |
UBI / UNIVERSAL BIOSENSORS INC / Cvc Ltd - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1)* Universal Biosensors, Inc. (Name of Issuer) Common Stock, par value US$0.0001 (Title of Class of Securities) Not Applicable (CUSIP Number) De |
|
| February 14, 2019 |
EX-1 2 tv513728ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT February 14, 2019 Pursuant to Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees that CVC Limited ("CVC") may file as necessary on behalf of the undersigned with the Securities and Exchange Commission a Schedule 13G or Schedule 13D and any amendments thereto |
|
| February 11, 2019 |
8-K 1 d699909d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) February 8, 2019 Universal Biosensors, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-52607 98-0424072 (State or Other Jurisdiction of |
|
| February 11, 2019 |
EX-99.1 Exhibit 99.1 Universal Biosensors, Inc. ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 11 February 2019 On February 8, 2019, Universal Biosensors, Inc. and Universal Biosensors Pty Ltd (“UBI”) entered into a term sheet agreement (the “Agreement”) with Sie |
|
| December 20, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 14, 2018 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 000-52607 98-0424072 (state or other jurisdiction of incorporation) (C |
|
| November 20, 2018 |
EX-99.1 Exhibit 99.1 Universal Biosensors Inc ARBN 121 559 993 1 Corporate Avenue Rowville VIC 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 20 November 2018 Prepayment of Loan Universal Biosensors (ASX: UBI) (‘Company’) today gave notice to Athyrium Opportunities Fund (A) LP to prepay the outstanding loan of US$15 |
|
| November 20, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 20, 2018 Universal Biosensors, Inc. (Exact Name of Issuer as Specified in Charter) DELAWARE 000-52607 98-0424072 (State or Other Jurisdiction of Incorporation or Organiza |
|
| November 8, 2018 |
UBI / UNIVERSAL BIOSENSORS INC / Cvc Ltd - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* Universal Biosensors, Inc. (Name of Issuer) Common Stock, par value US$0.0001 (Title of Class of Securities) Not Applicable (CUSIP Number) May |
|
| November 8, 2018 |
EX-1 2 tv506744ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT November 8, 2018 Pursuant to Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees that CVC Limited ("CVC") may file as necessary on behalf of the undersigned with the Securities and Exchange Commission a Schedule 13G or Schedule 13D and any amendments thereto |
|
| October 30, 2018 |
UBI / UNIVERSAL BIOSENSORS INC 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 28, 2018 |
EX-99.1 Exhibit 99.1 Universal Biosensors, Inc. ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 26 September 2018 Receipt of notice from LifeScan to buy out quarterly service fee obligation Universal Biosensors (ASX: UBI) today announced that it has received notic |
|
| September 28, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 26, 2018 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 000-52607 98-0424072 (state or other jurisdiction of incorporation) ( |
|
| August 13, 2018 |
UBI / UNIVERSAL BIOSENSORS INC 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 11, 2018 |
Chief Executive Officer’s Address Annual General Meeting EX-99.1 Exhibit 99.1 Universal Biosensors Inc ARBN 121 559 993 1 Corporate Avenue Rowville VIC 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 25 June 2018 Chief Executive Officer’s Address Annual General Meeting Good morning, ladies and gentlemen, I am happy to welcome you to our Rowville office for Universal Biosen |
|
| July 11, 2018 |
8-K 1 d425184d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 25, 2018 Universal Biosensors, Inc. (Exact Name of Issuer as Specified in Charter) DELAWARE 000-52607 98-0424072 (State or Other Jurisdiction of Incorpor |
|
| June 1, 2018 |
UBI / UNIVERSAL BIOSENSORS INC FORM SD SD 1 d595864dsd.htm FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Commission File Number: 000-52607 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 98-0424072 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Universal Biosensors, I |
|
| April 27, 2018 |
UBI / UNIVERSAL BIOSENSORS INC DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 27, 2018 |
UBI / UNIVERSAL BIOSENSORS INC 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 24, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 23, 2018 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 000-52607 98-0424072 (state or other jurisdiction of incorporation) (Comm |
|
| April 13, 2018 |
8-K 1 d561917d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 12, 2018 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 000-52607 98-0424072 (state or other jurisdiction of |
|
| February 23, 2018 |
EX-21 Exhibit 21 LIST OF SUBSIDIARIES Universal Biosensors Pty Ltd. Hemostasis Reference Laboratory Inc. |
|
| February 23, 2018 |
UVBIF / Universal Biosensors, Inc. 10-K (Annual Report) 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2017 OR ☐ Transition Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 000-52607 Universal Biosensors, Inc. (Exact name of registrant a |
|
| February 23, 2018 |
EX-32.0 Exhibit 32.0 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 * In connection with the annual report of Universal Biosensors, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers o |
|
| January 3, 2018 |
EX-10.1 Exhibit 10.1 Execution version AMENDMENT NO. 2 AND CONSENT TO CREDIT AGREEMENT This AMENDMENT NO. 2 AND CONSENT TO CREDIT AGREEMENT (this ?Agreement?) is made and entered into as of December 29, 2017 by and among UNIVERSAL BIOSENSORS PTY LTD (ACN 098 234 309), a proprietary limited company incorporated in Australia (the ?Borrower?), UNIVERSAL BIOSENSORS, INC., a Delaware corporation (?Pare |
|
| January 3, 2018 |
EX-99.1 Exhibit 99.1 Universal Biosensors, Inc. ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 2 January 2018 Extension of Athyrium term loan Universal Biosensors, Inc. (ASX: UBI) announced today that it has extended the maturity date of the term loan provided by |
|
| January 3, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2017 UNIVERSAL BIOSENSORS, INC. |
|
| October 24, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 7, 2017 |
Rick Legleiter Appointed Chief Executive Officer, Chairman Succession and Board Renewal Process EX-99.1 Exhibit 99.1 Universal Biosensors, Inc. ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 7 August 2017 Rick Legleiter Appointed Chief Executive Officer, Chairman Succession and Board Renewal Process Universal Biosensors, Inc. (ASX Code: UBI) (UBI) is please |
|
| August 7, 2017 |
Consultancy Agreement between UBS and Mr. Andrew Denver, dated August 7, 2017 EX-10.2 Exhibit 10.2 Consultancy Agreement dated 7 August 2017 Mr Andrew Denver 27 Woodville Ave Wahroonga NSW 2076 Dear Andrew, Universal Biosensors Pty Ltd (ACN 098 234 309) (UBI or the Company) is pleased to offer Mr Andrew Denver (ABN ) (the Consultant) engagement as an independent contractor for the provision of services on the terms and conditions contained in this Agreement. 1 Engagement 1. |
|
| August 7, 2017 |
Executive Service Agreement between UBS and Mr. Rick Legleiter, dated August 7, 2017 EX-10.1 Exhibit 10.1 Dated 7 August 2017 Chief Executive Officer ? Executive Service Agreement Parties Universal Biosensors Pty Ltd (ACN 098 234 309) Rick Legleiter Contents 1 Definitions and interpretation 1 2 Warranties 5 3 Commencement 5 4 Inherent Requirement 5 5 Position and Duties 6 6 Employer?s directions 7 7 Place of work 7 8 Hours of work 7 9 Remuneration 8 10 Equity Incentive Plan 8 11 S |
|
| August 7, 2017 |
UNIVERSAL BIOSENSORS FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 7, 2017 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 000-52607 98-0424072 (state or other jurisdiction of incorporation) |
|
| August 7, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 23, 2017 |
UNIVERSAL BIOSENSORS FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 22, 2017 Universal Biosensors, Inc. (Exact Name of Issuer as Specified in Charter) DELAWARE 000-52607 98-0424072 (State or Other Jurisdiction of Incorporation or Organiz |
|
| June 23, 2017 |
Chairman’s Address Annual General Meeting EX-99.1 Exhibit 99.1 Universal Biosensors Inc ARBN 121 559 993 1 Corporate Avenue Rowville VIC 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 22 June 2017 Chairman?s Address Annual General Meeting Good morning ladies & gentlemen and welcome to Universal Biosensor?s 2017 Annual General Meeting. Since our meeting last |
|
| May 25, 2017 |
Form SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Commission File Number: 000-52607 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 98-0424072 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Universal Biosensors, Inc. 1 Corporate Aven |
|
| April 27, 2017 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 21, 2017 |
DEF 14A 1 d343413ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by Registrant ☑ Filed by party other than Registrant ☐ Check the appropriate |
|
| March 21, 2017 |
EX-21 Exhibit 21 LIST OF SUBSIDIARIES Universal Biosensors Pty Ltd. Hemostasis Reference Laboratory Inc. |
|
| March 21, 2017 |
EX-32.0 Exhibit 32.0 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 * In connection with the annual report of Universal Biosensors, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers o |
|
| March 21, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 10, 2017 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 2, 2017 |
UBI / UNIVERSAL BIOSENSORS INC / Viburnum Funds Pty Ltd - SC 13D Activist Investment SC 13D 1 v458238sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934* Universal Biosensors, Inc. (Name of Issuer) Common Stock, par value US$0.0001 (Title of Class of Securities) Not Applicable (CUSIP Number) Viburnum Funds Pty Ltd Attention: David St Quintin 31 Carrington Street Nedlands, Western Australia, |
|
| February 2, 2017 |
EX-99.1 2 v458238ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT July 20, 2016 Pursuant to Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees that VIBURNUM FUNDS PTY LTD ("Viburnum") may file as necessary on behalf of the undersigned with the Securities and Exchange Commission a Schedule 13G or Schedule 13D and |
|
| October 20, 2016 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 21, 2016 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 20, 2016 |
Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints David St. |
|
| July 20, 2016 |
UBI / UNIVERSAL BIOSENSORS INC / Viburnum Funds Pty Ltd - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* Universal Biosensors, Inc. (Name of Issuer) Common Stock, par value US$0.0001 (Title of Class of Securities) Not Applicable (CUSIP Number) Jan |
|
| July 20, 2016 |
Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints David St. |
|
| July 20, 2016 |
Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints David St. |
|
| July 11, 2016 |
Exhibit 24.1 Power of Attorney Know all by these presents, that the undersigned hereby constitutes and appoints DAVID ST. QUINTIN with full power of substitution, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as a director of Universal Biosensors, Inc. (the ?Company?), Forms 3, 4, and 5 in accordance with Sect |
|
| June 30, 2016 |
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 30, 2016 Universal Biosensors, Inc. (Exact Name of Issuer as Specified in Charter) DELAWARE 000-52607 98-0424072 (State or Other Jurisdiction of Incorporation or Organiz |
|
| June 23, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 21, 2016 Universal Biosensors, Inc. (Exact Name of Issuer as Specified in Charter) DELAWARE 000-52607 98-0424072 (State or Other Jurisdiction of Incorporation or Organiz |
|
| June 23, 2016 |
EX-99.1 Exhibit 99.1 Universal Biosensors, Inc. ABN 51 121 559 993 1 Corporate Avenue Rowville Victoria 3149 Australia Telephone: +61 3 9213 9000 Facsimile: +61 3 9213 6490 Email: [email protected] www.universalbiosensors.com 21 June 2016 Dear Securityholder, Good morning ladies and gentlemen and welcome to the annual general meeting of Universal Biosensors. Your company is in the middl |
|
| June 1, 2016 |
FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Commission File Number: 000-52607 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 98-0424072 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Universal Biosensors, Inc. 1 Corporate Aven |
|
| April 28, 2016 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 21, 2016 |
Exhibit 10.2 March 4, 2016 UNIVERSAL BIOSENSORS PTY. LTD. 1 Corporate Avenue Rowville, Victoria 3178 Australia Re: Conditional Prepayment of Milestones and other amendments Ladies and Gentlemen: We refer to the Collaboration Agreement between Universal Biosensors Pty Ltd. (?UBI?) and Siemens Healthcare Diagnostics Inc. (?Siemens?) dated September 9, 2011 and as amended on September 20, 2012 (the ? |
|
| April 21, 2016 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 Commission File Number: 000-52607 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 98-0424072 (State or other jurisdiction |
|
| March 15, 2016 |
EX-32.0 Exhibit 32.0 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 * In connection with the annual report of Universal Biosensors, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers o |
|
| March 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 9, 2016 |
8-K 1 d156524d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 9, 2016 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 000-52607 98-0424072 (state or other jurisdictio |
|
| March 9, 2016 |
Universal Biosensors and Siemens agree modifications to collaboration arrangements EX-99.1 Exhibit 99.1 Universal Biosensors Inc ARBN 121 559 993 1 Corporate Avenue Rowville VIC 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 9 March 2016 Universal Biosensors and Siemens agree modifications to collaboration arrangements Universal Biosensors (ASX: UBI) announced today that it has agreed amendments t |
|
| March 8, 2016 |
Exhibit 24 LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all persons by these presents, that the undersigned hereby constitutes and appoints each of Cameron Billingsley, Salesh Balak, and Andrew Denver, signing singly, as the undersigned's true and lawful attorney-in-fact to: (1) Execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or a director of Universal Biosensors Inc. |
|
| March 3, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 2, 2016 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 000-52607 98-0424072 (state or other jurisdiction of incorporation) (Commissio |
|
| March 3, 2016 |
Universal Biosensors Appoints David Hoey as Non-Executive Director EX-99.1 Exhibit 99.1 Universal Biosensors, Inc. ABN 51 121 559 993 1 Corporate Avenue Rowville Victoria 3149 Australia Telephone: +61 3 9213 9000 Facsimile: +61 3 9213 6490 Email: [email protected] www.universalbiosensors.com 2 March 2016 Universal Biosensors Appoints David Hoey as Non-Executive Director Universal Biosensors, Inc. (ASX: UBI) today announced the appointment of Mr. David |
|
| February 19, 2016 |
Investor Presentation: FY2015 Financial Results Form EX-99.3 Exhibit 99.3 Investor Presentation: FY2015 Financial Results Important Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. This presentation is not financial advice and has been prepared without taking into account the objectives, financial situation or needs of a particular person. Neither |
|
| February 19, 2016 |
UNIVERSAL BIOSENSORS FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 17, 2016 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 000-52607 98-0424072 (state or other jurisdiction of incorporatio |
|
| February 19, 2016 |
Universal Biosensors Announces Retirement of CEO Paul Wright EX-99.1 Exhibit 99.1 Universal Biosensors Inc ARBN 121 559 993 1 Corporate Avenue Rowville VIC 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 19 February 2016 Universal Biosensors Announces Retirement of CEO Paul Wright Mr. Wright announced today his decision to retire as Chief Executive Officer of Universal Biosens |
|
| February 19, 2016 |
Employment Agreement between the Company and Andrew Denver, dated February 19, 2016. EX-10.2 Exhibit 10.2 Universal Biosensors Pty Ltd ABN 35 098 234 309 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9212 9000 Facsimile +61 3 9212 9099 Email [email protected] www.universalbiosensors.com 19 February 2016 Mr. Andrew Denver 27 Woodville Avenue Wahroonga NSW 2076 Dear Andrew, Letter of Offer and Terms of Employment Universal Biosensors Pty Ltd ACN 098 |
|
| February 19, 2016 |
UNIVERSAL BIOSENSORS 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 19, 2016 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 000-52607 98-0424072 (state or other jurisdiction of incorporation) (C |
|
| February 19, 2016 |
Separation Agreement between the Company and Paul Wright dated February 18, 2016. EX-10.1 2 d145408dex101.htm EX-10.1 Exhibit 10.1 Universal Biosensors Pty Ltd ABN 35 098 234 309 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 18 February 2016 Mr. Paul Wright 3/1 Chatsworth Avenue Brighton VIC 3186 Dear Paul, Following our discussion on 17 February 2016, I conf |
|
| February 19, 2016 |
Form EX-99.1 Exhibit 99.1 Universal Biosensors, Inc. ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 17th February 2016 Universal Biosensors announces FY2015 results showing strong revenue growth and positive operating cash flow Highlights of FY2015 ? Revenue from |
|
| February 19, 2016 |
Form EX-99.2 Exhibit 99.2 Universal Biosensors, Inc. ASX Preliminary final report ? December 31, 2015 Lodged with the ASX under Listing Rule 4.3A This report is to be read in conjunction with any public announcements made during the reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001 (Cth) and the Listing Rules of the Australian Securities Exchan |
|
| October 29, 2015 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 29, 2015 |
Exhibit 24 LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all persons by these presents, that the undersigned hereby constitutes and appoints each of Cameron Billingsley, Salesh Balak, and Paul Wright, signing singly, as the undersigned's true and lawful attorney-in-fact to: (1) Execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or a director of Universal Biosensors Inc. |
|
| August 14, 2015 |
UNIVERSAL BIOSENSORS FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 11, 2015 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 000-52607 98-0424072 (state or other jurisdiction of incorporation) |
|
| August 14, 2015 |
Universal Biosensors Board Resignation EX-99.1 2 d45538dex991.htm EX-99.1 Exhibit 99.1 11 August 2015 Universal Biosensors Board Resignation Universal Biosensors, Inc. (ASX: UBI) announced today that Mr. Chris Smith has advised that he will resign as a director, effective 30 August 2015. Mr. Smith is stepping down to focus on his new role as Chief Executive Officer of Cochlear Limited which commences on 1 September 2015. UBI Chairman A |
|
| July 23, 2015 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 Commission File Number: 000-52607 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 98-0424072 (State or other jurisdiction o |
|
| July 13, 2015 |
UNIVERSAL BIOSENSORS 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 9, 2015 Universal Biosensors, Inc. (Exact Name of Issuer as Specified in Charter) DELAWARE 000-52607 98-0424072 (State or Other Jurisdiction of (Commission (I.R.S. Employer I |
|
| May 19, 2015 |
FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Commission File Number: 000-52607 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 98-0424072 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Universal Biosensors, Inc. 1 Corporate Aven |
|
| April 29, 2015 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 27, 2015 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 Commission File Number: 000-52607 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 98-0424072 (State or other jurisdiction |
|
| March 20, 2015 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 18, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 12, 2015 Universal Biosensors, Inc. (Exact name of registrant as specified in its charter) Delaware 000-52607 98-0424072 (state or other jurisdiction of incorporation) (Commissi |
|
| March 12, 2015 |
Report of Independent Registered Public Accounting Firm EX-13.0 Table of Contents Exhibit 13 Universal Biosensors, Inc. 2014 Annual Report Contents Management’s Discussion and Analysis of Financial Condition and Results of Operations F-2 Report of Independent Registered Public Accounting Firm F-16 Consolidated Balance Sheets F-18 Consolidated Statements of Comprehensive Income F-19 Consolidated Statements of Changes in Stockholders’ Equity and Comprehe |
|
| March 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2014 OR ? Transition Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 000-52607 Universal Biosensors, Inc. (Exact name of |
|
| March 12, 2015 |
EX-32.0 Exhibit 32.0 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 * In connection with the annual report of Universal Biosensors, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers o |
|
| February 2, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2015 UNIVERSAL BIOSENSORS, INC. |
|
| February 2, 2015 |
EX-10.1 Exhibit 10.1 AMENDMENT NO. 1 TO CREDIT AGREEMENT This AMENDMENT AGREEMENT (this “Agreement”) is made and entered into as of January 30, 2015 by and among UNIVERSAL BIOSENSORS PTY LTD (ACN 098 234 309), a proprietary limited company incorporated in Australia (the “Borrower”), UNIVERSAL BIOSENSORS, INC., a Delaware corporation (the “Guarantor”), ATHYRIUM OPPORTUNITIES FUND (A) LP, as Adminis |
|
| February 2, 2015 |
Extension of option to draw additional funds from the Athyrium term loan facility EX-99.1 Exhibit 99.1 Universal Biosensors Inc ARBN 121 559 993 1 Corporate Avenue Rowville VIC 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email [email protected] www.universalbiosensors.com 2 February 2015 Extension of option to draw additional funds from the Athyrium term loan facility Universal Biosensors, Inc. (ASX: UBI) announced today that it has chosen not |
|
| October 29, 2014 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
